15 results on '"N. Plouvier"'
Search Results
2. Next-generation biological control
- Author
-
Eveline C. Verhulst, Louis van de Zande, Alejandra Centurión, Kelley Leung, Leo W. Beukeboom, Alberto Urbaneja, Jacques Brodeur, Dirk Babendreier, Marcel Dicke, John H. Werren, Angeliki Paspati, Sara Magalhães, Milena Chinchilla-Ramírez, Manolis Lyrakis, Joel González-Cabrera, Sophie R. Chattington, Andra Thiel, Panagiota Koskinioti, Erica Ras, Kostas Bourtzis, Margreet A. Bruins, Bart A. Pannebakker, Wouter N. Plouvier, Sophie Le Hesran, Simone Ariëns, Christian Schlötterer, Judith M. Stahl, Nina E. Fatouros, Tim Haye, Piter Bijma, Meritxell Pérez-Hedo, Thomas Groot, Kim B. Ferguson, Bas J. Zwaan, Markus Knapp, Shuwen Xia, Louise E. M. Vet, Sander Visser, University of Groningen [Groningen], Vienna International Centre, International Atomic Energy Agency [Vienna] (IAEA), Wageningen University and Research [Wageningen] (WUR), University of Bremen, CABI Europe Switzerland, Université de Montréal (UdeM), Instituto Valenciano de Investigaciones Agrarias - Institut Valencià d'Investigacions Agraries - Valencian Institute for agricultural Research (IVIA), Universitat de València (UV), Koppert Biological Systems, Vetmeduni Vienna, Vienna Graduate School of Finance (VGSF), Institut Sophia Agrobiotech (ISA), Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Centre National de la Recherche Scientifique (CNRS)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Université Côte d'Azur (UCA), Institut für Populationsgenetik [Vienna], Veterinärmedizinische Universität Wien, University of California [Berkeley], University of California, Universität Bremen, Biology Centre of the Czech Academy of Sciences (BIOLOGY CENTRE CAS), Czech Academy of Sciences [Prague] (CAS), South Bohemian Research Center of Aquaculture and Biodiversity of Hydrocenoses [University of South Bohemia] (CENAKVA), Faculty of Fisheries and Protection of Waters [University of South Bohemia], University of South Bohemia -University of South Bohemia, University of Rochester [USA], Universidade de Lisboa (ULISBOA), Department of Mathematics (University of Groningen), European Project: 641456,H2020,H2020-MSCA-ITN-2014,BINGO(2015), Repositório da Universidade de Lisboa, Beukeboom lab, Van de Zande lab, Université Nice Sophia Antipolis (1965 - 2019) (UNS), University of California [Berkeley] (UC Berkeley), University of California (UC), and Universidade de Lisboa = University of Lisbon (ULISBOA)
- Subjects
0106 biological sciences ,Proteomics ,H10 Pests of plants ,Internationality ,Computer science ,[SDV]Life Sciences [q-bio] ,Laboratory of Virology ,Sequence assembly ,biological control ,microbiome ,01 natural sciences ,Genome editing ,genetics ,Nagoya Protocol ,Laboratory of Entomology ,CYTOPLASMIC INCOMPATIBILITY ,2. Zero hunger ,0303 health sciences ,QUANTITATIVE TRAIT LOCI ,Commerce ,food and beverages ,CONTROL AGENTS ,PE&RC ,Biosystematiek ,NASONIA-VITRIPENNIS ,GUT CONTENT-ANALYSIS ,[SDE]Environmental Sciences ,Trait ,insect breeding ,AXYRIDIS COLEOPTERA-COCCINELLIDAE ,Original Article ,Laboratory of Genetics ,LIFE-HISTORY TRAITS ,General Agricultural and Biological Sciences ,Genomics ,Context (language use) ,Computational biology ,[SDV.BID]Life Sciences [q-bio]/Biodiversity ,artificial selection ,Quantitative trait locus ,Animal Breeding and Genomics ,Laboratorium voor Erfelijkheidsleer ,010603 evolutionary biology ,General Biochemistry, Genetics and Molecular Biology ,Laboratorium voor Virologie ,modelling ,03 medical and health sciences ,genomics ,[SDV.BV]Life Sciences [q-bio]/Vegetal Biology ,Fokkerij en Genomica ,PARASITOID WASP ,Selection (genetic algorithm) ,030304 developmental biology ,SEX DETERMINATION ,Original Articles ,Laboratorium voor Entomologie ,WIAS ,genome assembly ,Biosystematics ,EPS ,artificial selection, biological control, genetics, genome assembly, genomics, insect breeding, microbiome, modelling - Abstract
Biological control is widely successful at controlling pests, but effective biocontrol agents are now more difficult to import from countries of origin due to more restrictive international trade laws (the Nagoya Protocol). Coupled with increasing demand, the efficacy of existing and new biocontrol agents needs to be improved with genetic and genomic approaches. Although they have been underutilised in the past, application of genetic and genomic techniques is becoming more feasible from both technological and economic perspectives. We review current methods and provide a framework for using them. First, it is necessary to identify which biocontrol trait to select and in what direction. Next, the genes or markers linked to these traits need be determined, including how to implement this information into a selective breeding program. Choosing a trait can be assisted by modelling to account for the proper agro-ecological context, and by knowing which traits have sufficiently high heritability values. We provide guidelines for designing genomic strategies in biocontrol programs, which depend on the organism, budget, and desired objective. Genomic approaches start with genome sequencing and assembly. We provide a guide for deciding the most successful sequencing strategy for biocontrol agents. Gene discovery involves quantitative trait loci analyses, transcriptomic and proteomic studies, and gene editing. Improving biocontrol practices includes marker-assisted selection, genomic selection and microbiome manipulation of biocontrol agents, and monitoring for genetic variation during rearing and post-release. We conclude by identifying the most promising applications of genetic and genomic methods to improve biological control efficacy
- Published
- 2020
- Full Text
- View/download PDF
3. Dysfonction endothéliale et défaut de réponse au réentraînement à l’effort dans la BPCO–Mobilisation des progéniteurs endothéliaux circulants
- Author
-
F. Gouzi, S. Günther, L. Blervaque, M. Gruest, A. Philippe, J. Rancic, N. Gendron, C. Hédon, N. Heraud, A. Perez-Martin, A. Virsolvy, O. Cazorla, G. Condurache, N. Plouvier, A. Proust, Y. Dauvilliers, M. Hayot, E. Rossi, and D. Smadja
- Subjects
Pulmonary and Respiratory Medicine - Published
- 2022
- Full Text
- View/download PDF
4. Genetic Variation of Traits in Natural Enemies Relevant for Biological Control: A Systematic Review
- Author
-
Chattington, Wouter N. Plouvier, Bart A. Pannebakker, and Kim B. Ferguson
- Subjects
0106 biological sciences ,010602 entomology ,Evolutionary biology ,Genetic variation ,Biological pest control ,Natural enemies ,Biology ,Heritability ,entomology ,010603 evolutionary biology ,01 natural sciences ,Life history theory - Abstract
The concept of genetic improvement in relation to biological control involves the exploitation of natural genetic variation for the benefit of existing biological control agents (BCAs). Despite recent calls for this process to be adopted in biological control research, there is no clear overview of the current state of research into genetic variation within a biological control context, including quantifiable estimates such as narrow-sense heritability (h2). In this systematic review, we aim to determine the current state of research on the genetic variation of biological control traits in natural enemies. After the searching process, screening for papers that can deliver on our research question reduced the initial 2,927 search hits to only a mere 69 papers for data extraction. Of these, the majority (73.6%) did not report quantitative values for genetic variation. Extracting the traits measured in these papers, we categorized them according to two approaches; the first related to fitness components, and the second related to biological control importance. This systematic review highlights the need for more rigorous reporting of the quantitative values of genetic variation to enable the successful genetic improvement of biological control agents.
- Published
- 2020
- Full Text
- View/download PDF
5. Next Generation Biological Control: The Need for Integrating Genetics and Evolution
- Author
-
Eveline C. Verhulst, Piter Bijma, Louis van de Zande, Manolis Lirakis, Kelley Leung, Andra Thiel, Leo W. Beukeboom, Christian Schlötterer, Alejandra Centurión, Angeliki Paspati, John H. Werren, Sophie R. Chattington, Bas J. Zwaan, Bart A. Pannebakker, Tim Haye, Sander Visser, Alberto Urbaneja, Shuwen Xia, Panagioata Koskinioti, Erica Ras, Sara Magalhães, Markus Knapp, Milena Chinchilla-Ramírez, Nina E. Fatouros, Sophie Le Hesran, Kostas Bourtzis, Meritxell Pérez-Hedo, Jacques Brodeur, Dirk Babendreier, Kim B. Ferguson, Joel González Cabrera, Margreet A. Bruins, Louise E. M. Vet, Thomas Groot, Judith M. Stahl, Marcel Dicke, Simone Ariëns, Wouter N. Plouvier, and Terrestrial Ecology (TE)
- Subjects
2. Zero hunger ,0106 biological sciences ,Plan_S-Compliant-TA ,biological control ,microbiome ,food and beverages ,Sequence assembly ,Genomics ,artificial selection ,Computational biology ,Biology ,entomology ,010603 evolutionary biology ,01 natural sciences ,modelling ,010602 entomology ,international ,genome assembly ,genomics ,insect breeding ,genetics ,Microbiome - Abstract
Biological control is widely successful for controlling pests, but effective biocontrol agents are now more difficult to obtain due to more restrictive international trade laws. Coupled with increasing demand, the efficacy of existing and new biocontrol agents needs to be improved with genetic and genomic approaches. Although they have been underutilised in the past, applying genetic and genomic techniques is becoming more feasible from both technological and economic perspectives. We review current methods and provide a framework for using them, incorporating evolutionary and ecological principles. First, it is necessary to identify which biocontrol trait to select and in what direction. Next, the genes or markers linked to these traits need be determined to better target their selection, followed by how to implement this information into a breeding program. Choosing a trait can be assisted by modelling to account for the proper agro-ecological context, and by knowing which traits have sufficiently high heritability values. We provide guidelines for designing genomic strategies in biocontrol programs, which depends on the organism, budget, and desired objective. Genomic approaches start with genome sequencing and assembly. We provide a guide for deciding the most successful sequencing strategy for biocontrol agents. Gene discovery involves quantitative trait loci (QTL) analyses, transcriptomic and proteomic studies, and gene editing. Improving biocontrol practices include marker-assisted selection, genomic selection and microbiome manipulation of biocontrol agents, and monitoring for genetic variation during rearing and post-release. We conclude by identifying the most promising applications of genetic and genomic methods to improve biological control efficacy.
- Published
- 2019
- Full Text
- View/download PDF
6. Hyponatrémie sévère sous chimiothérapie du carcinome à petites cellules
- Author
-
H. Bentayeb, R. Suguenot, R. Cotrel, E. Lecuyer, Charles Dayen, C. Garoute, E. Iacob, Youcef Douadi, and N. Plouvier
- Subjects
Pulmonary and Respiratory Medicine ,Gynecology ,medicine.medical_specialty ,business.industry ,Syndrome of inappropriate antidiuretic hormone secretion ,medicine ,business ,medicine.disease - Abstract
Resume Introduction Le carcinome a petites cellules (CPC) est un cancer rapidement evolutif de tres mauvais pronostic. Sa chimio-sensibilite implique un traitement rapide. L’hyponatremie du CPC rapportee au syndrome de secretion inappropriee d’hormone antidiuretique est classique. Nous rapportons un cas d’hyponatremie severe induite par la chimiotherapie ayant entraine une prise en charge de soins intensifs. Observation Un patient âge de 68 ans est pris en charge pour un cancer bronchique a petites cellules envahissant le poumon droit. A la premiere cure, le patient presente un coma necessitant une prise en charge en soins intensifs le deuxieme jour (j2) de chimiotherapie (cisplatine-vepeside) qui est rapporte a une hyponatremie severe (107 mmol/L) et d’evolution favorable sous therapeutiques specifiques. Le patient presentera ces memes episodes aux j2 des cures suivantes mais avec des manifestations cliniques de moins en moins intenses. Conclusions La notion d’hyponatremie induite par la chimiotherapie du CPC est peu connue. Ce cas clinique met en evidence le risque d’hyponatremie severe sous chimiotherapie du carcinome a petites cellules. Celle-ci pourrait etre correlee a la fonte tumorale. Une surveillance biologique lors du j2 de chimiotherapie est preconisee.
- Published
- 2015
- Full Text
- View/download PDF
7. Hyponatrémie sévère sous chimiothérapie du carcinome à petites cellules
- Author
-
C, Garoute, N, Plouvier, E, Iacob, R, Cotrel, R, Suguenot, E, Lecuyer, H, Bentayeb, Y, Douadi, C, Dayen, Centre hospitalier de Saint-Quentin, and Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)
- Subjects
Male ,Lung Neoplasms ,Syndrome of inappropriate antidiuretic hormone secretion ,Small cell lung cancer ,nutritional and metabolic diseases ,Cancer bronchique à petites cellules ,[SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract ,Inappropriate ADH Syndrome ,Syndrome de sécrétion inappropriée d’hormone antidiurétique ,Recurrence ,Antineoplastic Combined Chemotherapy Protocols ,Humans ,Chemotherapy ,Carcinoma, Small Cell ,Cisplatin ,Coma ,Hyponatrémie ,Tomography, X-Ray Computed ,Chimiothérapie ,Aged ,Etoposide ,Hyponatremia - Abstract
International audience; INTRODUCTION:The small cell lung cancer (SCLC) is a rapidly progressive malignancy with a poor prognosis. Its chemosensitivity mandates prompt treatment. Hyponatremia occurs frequently in patients with small cell lung cancer due to the syndrome of inappropriate antidiuretic hormone (SIADH). We report a case of severe hyponatremia induced by chemotherapy that required management in intensive care.OBSERVATION:A 68-year-old patient was undergoing treatment for small cell cancer, invading the right lung. On the second day of the first cycle of treatment (cisplatine-vepeside), the patient became comatose and required transfer to an intensive care unit. The coma was due to severe hyponatremia (107 mmol/L) and improved with specific treatment. The patient had similar episodes on the second day of each chemotherapy treatment but with less and less severe clinical manifestations. Hyponatremia due to chemotherapy in SCLC is not commonly known; a relation between hyponatremia intensity and the tumor size is suspected.CONCLUSION:This clinical case highlights the possibility of severe hyponatremia during small cell lung cancer chemotherapy. Hyponatremia may be related to the reduction in tumor size. Monitoring of electrolytes on day 2 of chemotherapy is advised.
- Published
- 2015
- Full Text
- View/download PDF
8. Prise en charge des exacerbations aiguës de BPCO au CHU d’Amiens. Évaluation des pratiques professionnelles en 2010 et 2012
- Author
-
C. Trouve, I. Rault, C. Hybiak, Vincent Jounieaux, N. Plouvier, Claire Andrejak, and J.B. Obstler
- Subjects
Pulmonary and Respiratory Medicine - Abstract
La BPCO, maladie chronique respiratoire frequente, est un probleme de sante publique. L’objectif de ce travail etait d’evaluer la mise en place d’une evaluation des pratiques professionnelles concernant la prise en charge des exacerbations de BPCO au sein du CHU d’Amiens. Les donnees concernant la prise en charge etaient comparees avant (periode 1) et apres (periode 2) diffusion des recommandations emises par la Societe de pneumologie de langue francaise. Durant 2 ans, 63 patients etaient inclus (âge moyen 62 ans). Les prescriptions de salbutamol et de sulfate de magnesium par voie intraveineuse etaient diminuees de maniere significative entre la periode 1 et la periode 2, respectivement 61 % contre 10 % ( p p = 0,001). De meme que l’utilisation de fluidifiants bronchiques (50 % contre 16 %, p = 0,004). Les prescriptions de corticoides et d’antibiotiques etaient plus en accord avec les recommandations (34 % contre 77 %, p = 0,001 et 62 % contre 87 %, p = 0,024). Des resultats similaires etaient observes dans l’analyse en sous-groupe. La kinesitherapie respiratoire etait prescrite a tous les patients en periode 2. On ne retrouvait pas de difference significative sur la duree d’hospitalisation (mediane de 8 jours). Tous les patients hospitalises durant la periode 2 ont beneficie d’un conseil minimal contre 86 % des patients hospitalises en periode 1. Notre etude montre une importante modification des pratiques cliniques apres diffusion des recommandations avec une amelioration de la prise en charge et montre qu’il existe un interet majeur a la realisation d’EPP pour ameliorer la prise en charge des exacerbations aigues de BPCO.
- Published
- 2015
- Full Text
- View/download PDF
9. Diagnostic des adénopathies médiastinales par EBUS-TBNA (endobronchial ultrasound-guided transbronchial needle aspiration) : résultats à propos de 425 procédures sur quatre ans
- Author
-
N. Trouillet, E. Lecuyer, S. Carton, R. Suguenot, H. Bentayeb, L. Andre, P. Dumon, Youcef Douadi, F. Amirats, N. Plouvier, M. Boutemy, D. Amar, and Charles Dayen
- Subjects
Pulmonary and Respiratory Medicine - Published
- 2013
- Full Text
- View/download PDF
10. Évaluation d’un nouveau score de qualité de vie simplifié pour l’évaluation de la BPCO en médecine générale. Étude prospective
- Author
-
N. Plouvier, H. Bentayeb, Vincent Jounieaux, Claire Andrejak, R. Suguenot, E. Lecuyer, O. Carré, D. Amar, Youcef Douadi, D. Proisy, Charles Dayen, and M. Boutemy
- Subjects
Pulmonary and Respiratory Medicine - Published
- 2013
- Full Text
- View/download PDF
11. Improving the efficiency of augmentative biological control with arthropod natural enemies: A modeling approach
- Author
-
Eric Wajnberg, Wouter N. Plouvier, Institut Sophia Agrobiotech (ISA), Centre National de la Recherche Scientifique (CNRS)-Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut National de la Recherche Agronomique (INRA), Wageningen University and Research Centre (WUR), European Project: 641456,H2020,H2020-MSCA-ITN-2014,BINGO(2015), Institut National de la Recherche Agronomique (INRA)-Université Nice Sophia Antipolis (1965 - 2019) (UNS), and COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Centre National de la Recherche Scientifique (CNRS)
- Subjects
0106 biological sciences ,Individual-based model ,Ecology (disciplines) ,media_common.quotation_subject ,[SDV]Life Sciences [q-bio] ,Population ,Natural enemies ,Behavioral ecology ,Biology ,Laboratorium voor Erfelijkheidsleer ,010603 evolutionary biology ,01 natural sciences ,Competition (biology) ,Life history theory ,Cost efficiency ,Life-history traits ,education ,media_common ,2. Zero hunger ,education.field_of_study ,Longevity ,15. Life on land ,Environmental economics ,PE&RC ,010602 entomology ,Genetic algorithm ,Insect Science ,[SDE]Environmental Sciences ,Biological dispersal ,Identification (biology) ,Laboratory of Genetics ,Agronomy and Crop Science - Abstract
International audience; A better understanding of the life-history traits of biocontrol agents and their effect on population dynamics is key to obtaining more efficient pest control and generating higher economic returns for biocontrol practitioners. To this end, we constructed an optimality simulation model based on principles of the behavioral ecology of natural enemies. This model allows for the identification of the most important life-history traits of natural enemies (e.g., fecundity, longevity, attack rate, competition and dispersal), taking into account the costs and benefits for biocontrol practitioners. The model was kept general and was designed in such a way that it can be adapted to different target species and their specific ecology (natural enemy-pest-plant combination). Results indicate strong interactions between the optimized life-history traits of the biocontrol agents. Two different optimized life-history strategies for the agents were found with higher potential economic returns. These strategies differ most significantly in the plant-leaving decision and host handling time of the biocontrol agent, but also in their respective fecundity, longevity and dispersal ability. The preferred strategy depends on the number of agents released and the growth rate of the plant. Information from these optimality models can help to determine which agents should be released and how they should be released in a specific agro-ecological situation.
- Full Text
- View/download PDF
12. Clinical impact of pharmaceutical consultations in patients treated for chronic obstructive pulmonary disease: Study protocol for a randomized controlled trial (BPCObs study).
- Author
-
Hachemi D, Leguelinel-Blache G, Bouvet S, Roux-Marson C, Plouvier N, Kinowski JM, Castelli C, and Dubois F
- Abstract
Background: Chronic obstructive pulmonary disease (COPD) is an irreversible chronic respiratory disease which outcome depends on medication adherence. Pharmacists may increase this adherence by advising patients on inhaler devices proper use. This paper presents the protocol for a randomized controlled trial, which assesses impact of pharmaceutical consultations on COPD exacerbations, medical care, adherence to inhaler devices and quality of life., Methods: This trial will include 226 COPD patients treated with inhaler devices: 94 in a control group, 66 receiving a pharmaceutical consultation at hospital and 66 receiving up to 12 pharmaceutical consultations corresponding to dispensing at their community pharmacy. The aim of these interventions is to inform patients about COPD medication, train them in the use of inhaler devices and improve adherence. Patients included by hospital pharmacist will be randomly assigned to the control and hospital experimental groups. Community pharmacists (CP) will include patients in the experimental community group. CPs will follow-up all study patients for 12 months. Primary outcome is the mean number of COPD exacerbations. Secondary outcomes include number of medical consultations, emergency visits and hospitalizations, patients' adherence devices and quality of life., Discussion: This is the first French trial which assesses both hospital and community pharmaceutical interventions on COPD patients. Study limitations include recruitment and CP adherence to follow-up. Indeed, the success of this trial depends on the willingness of CPs to collect the data. This work is the first step towards building a network of CPs trained for clinical research., Trial Registration: Clinicaltrials.gov, NCT03704545. Registered on October 12th, 2018. https://clinicaltrials.gov/ct2/show/NCT03704545?cond=COPD&cntry=FR&city=nimes&draw=2&rank=1., Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (© 2024 Published by Elsevier Inc.)
- Published
- 2023
- Full Text
- View/download PDF
13. Sacubitril-valsartan initiation in chronic heart failure patients impacts sleep apnea: the ENTRESTO-SAS study.
- Author
-
Jaffuel D, Nogue E, Berdague P, Galinier M, Fournier P, Dupuis M, Georger F, Cadars MP, Ricci JE, Plouvier N, Picard F, Puel V, Mallet JP, Suehs CM, Molinari N, Bourdin A, and Roubille F
- Subjects
- Aged, Aminobutyrates, Biphenyl Compounds, Cohort Studies, Drug Combinations, Female, Humans, Male, Prospective Studies, Stroke Volume, Valsartan, Ventricular Function, Left, Heart Failure complications, Heart Failure drug therapy, Sleep Apnea Syndromes drug therapy, Sleep Apnea Syndromes epidemiology
- Abstract
Aims: Optimizing medical cardiac treatment for sleep apnoea (SA) in patients with chronic heart failure and reduced ejection fraction (HFrEF) is an expert Grade C recommendation based on six studies encompassing a total of 67 patients only. Whether sacubitril-valsartan (SV), a cornerstone of HFrEF medical treatment, impacts SA is unknown and requires evaluation., Methods and Results: The ENTRESTO-SAS trial is a six-centre, prospective, open-label real-life cohort study (NCT02916160). Ambulatory patients eligible for SV (i.e. HFrEF adults who remain symptomatic despite optimal treatment) were evaluated before and after 3 months of SV (including nocturnal ventilatory polygraphy); 118 patients were final analysed [median age was 66 (IQ
25-75 : 56-73) years, 81.4% male, 36.5% New York Heart Association III-IV, N-terminal pro-B-type natriuretic peptide level of 1564 (701-3376) ng/L, left ventricular ejection fraction of 30 (25-34)%, 60.7% ischaemic HFrEF, 97.5% initially treated with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers, 83.9% with beta-blockers, 64.4% with mineralocorticoid receptor antagonists, and 74.6% with diuretics]. Three groups were defined according to initial central/obstructive apnoea-hypopnoea indices (AHIs): G1 (n = 49, AHIcentral ≥ 5/h and AHIobstructive < 15/h); G2 (n = 27, AHIobstructive ≥ 15/h); and G3 (n = 42, AHIcentral < 5/h and AHIobstructive < 15/h). At 3 months, the AHI (main predefined outcome) decreased significantly by -7.10/h (IQ25-75 : -16.10 to 0.40; P < 0.001) in G1 + G2 without positive airway pressure treatment (45 patients, median initial AHI of 24.20 (IQ25-75 : 16.40-43.50)/h). Of these, 24.4% presented an AHI decrease ≥50% and 37.78% had a final AHI < 15/h (tendency for improvement from an initial value of 20%: P = 0.0574). For G1 patients (n = 37), AHI significantly decreased from a median of 22.90 (16.00-43.50)/h to 19.20 (12.70-31.10)/h (P = 0.002). For G2 patients (n = 8), AHI decreased from a median of 30.10 (26.40-47.60)/h to 22.75 (14.60-36.90)/h (statistically non-significant, P = 0.059)., Conclusions: In this real-life population, SV treatment for 3 months in SA patients is associated with a significant decrease in AHI. These results support the current guidelines that recommend first an optimization of the HFrEF treatment in patients with HFrEF and central SA. A potential positive airway pressure sparing effect merits further investigation., (© 2021 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.)- Published
- 2021
- Full Text
- View/download PDF
14. Non-steroidal Anti-inflammatory Drugs may Worsen the Course of Community-Acquired Pneumonia: A Cohort Study.
- Author
-
Basille D, Plouvier N, Trouve C, Duhaut P, Andrejak C, and Jounieaux V
- Subjects
- Adult, Aged, Aged, 80 and over, Alcoholism complications, Anti-Bacterial Agents therapeutic use, Anti-Inflammatory Agents, Non-Steroidal therapeutic use, Community-Acquired Infections complications, Community-Acquired Infections drug therapy, Female, Humans, Intensive Care Units, Length of Stay, Male, Middle Aged, Patient Admission, Pneumonia drug therapy, Prospective Studies, Risk Factors, Time-to-Treatment, Anti-Inflammatory Agents, Non-Steroidal adverse effects, Lung Abscess etiology, Pleural Effusion etiology, Pneumonia complications
- Abstract
Purpose: Non-steroidal anti-inflammatory drugs (NSAIDs) are frequently prescribed or used as self-medication in cases of community-acquired pneumonia (CAP). Nevertheless, the consequences of such medication on the risk of pleuroparenchymal complications are not well known. The aim was to investigate whether exposure to NSAIDs prior to hospital admission among patients suffering from CAP is associated with the development of pleural complications or a lung abscess., Methods: All consecutive non-immunocompromised patients with CAP and admitted to a university hospital were prospectively included (2-year period). The risk of pleuropulmonary complications was analyzed according to previous exposure to NSAIDs., Results: Of the 221 included patients, 40 (18.1%) had developed a pleuropulmonary complication. NSAIDs intake prior to admission was reported for 24 patients (10.9%) who were younger (50.6 ± 18.5 vs. 66.5 ± 16.4 years; p = 0.001), had less comorbidities (60 vs. 25.1%; p = 0.001), had a longer duration between the first symptoms of CAP and the start of an antibiotic therapy (6.1 ± 7.6 vs. 2.8 ± 3.8 days; p = 0.001), and who had a higher incidence of pleuropulmonary complications (33.3 vs. 16.2%; p = 0.048). In multivariate analyses, two factors were independently associated with the development of pleuroparenchymal complications: NSAIDs intake [Odds Ratio (OR) = 2.57 [1.02-6.64]; p = 0.049] and alcohol abuse (OR = 2.68 [1.27-5.69]; p = 0.01)., Conclusions: Our findings suggest that NSAIDs, often taken by young and healthy patients, may worsen the course of CAP with delayed therapy and a higher rate of pleuropulmonary complications.
- Published
- 2017
- Full Text
- View/download PDF
15. [Severe hyponatremia during chemotherapy for small cell carcinoma].
- Author
-
Garoute C, Plouvier N, Iacob E, Cotrel R, Suguenot R, Lecuyer E, Bentayeb H, Douadi Y, and Dayen C
- Subjects
- Aged, Carcinoma, Small Cell complications, Cisplatin administration & dosage, Coma etiology, Etoposide administration & dosage, Humans, Inappropriate ADH Syndrome blood, Lung Neoplasms complications, Male, Recurrence, Tomography, X-Ray Computed, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Carcinoma, Small Cell drug therapy, Hyponatremia etiology, Inappropriate ADH Syndrome etiology, Lung Neoplasms drug therapy
- Abstract
Introduction: The small cell lung cancer (SCLC) is a rapidly progressive malignancy with a poor prognosis. Its chemosensitivity mandates prompt treatment. Hyponatremia occurs frequently in patients with small cell lung cancer due to the syndrome of inappropriate antidiuretic hormone (SIADH). We report a case of severe hyponatremia induced by chemotherapy that required management in intensive care., Observation: A 68-year-old patient was undergoing treatment for small cell cancer, invading the right lung. On the second day of the first cycle of treatment (cisplatine-vepeside), the patient became comatose and required transfer to an intensive care unit. The coma was due to severe hyponatremia (107 mmol/L) and improved with specific treatment. The patient had similar episodes on the second day of each chemotherapy treatment but with less and less severe clinical manifestations. Hyponatremia due to chemotherapy in SCLC is not commonly known; a relation between hyponatremia intensity and the tumor size is suspected., Conclusion: This clinical case highlights the possibility of severe hyponatremia during small cell lung cancer chemotherapy. Hyponatremia may be related to the reduction in tumor size. Monitoring of electrolytes on day 2 of chemotherapy is advised., (Copyright © 2014 SPLF. Published by Elsevier Masson SAS. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.